Instil Bio, Inc. (TIL): Cash & Equivalents
$6.64M
As of 2025-12-31
$5.54M
As of 2026-06-30
-46.7%
3-year compound annual growth
-51.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.64M | -24.6% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $8.80M | -4.2% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $9.20M | -79.0% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $43.72M | +16.3% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $37.59M | -84.4% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $241.71M | n/a | 2022-03-07, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | 2025-12-31 | $6.64M | -24.6% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $49.66M | -69.5% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $182.53M | +28.4% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $30.64M | -29.5% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $41.72M | +52.3% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $50.15M | -71.0% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $61.85M | +5.8% |
| Agenus Inc (AGEN) | 2025-12-31 | $3.00M | -92.6% |
Compare TIL, TARA, NMRA, CMPX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗